NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

Saved in:
Bibliographic Details
Title: NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.
Authors: Freeman TJ; NSABP Foundation, Inc, Pittsburgh, PA, USA. Tanner.Freeman@NSABP.org.; University of Pittsburgh, Pittsburgh, PA, USA. Tanner.Freeman@NSABP.org., George TJ; NSABP Foundation, Inc, Pittsburgh, PA, USA.; The University of Florida Health Cancer Center, Gainesville, FL, USA., Jacobs SA; NSABP Foundation, Inc, Pittsburgh, PA, USA., Yothers G; University of Pittsburgh, Pittsburgh, PA, USA.; NSABP/NRG Oncology, Pittsburgh, PA, USA., Kolevska T; Kaiser Permanente Northern California, Vallejo, CA, USA., Feng H; NSABP Foundation, Inc, Pittsburgh, PA, USA., Lipchik C; NSABP Foundation, Inc, Pittsburgh, PA, USA., Maley S; NSABP Foundation, Inc, Pittsburgh, PA, USA., Song N; NSABP Foundation, Inc, Pittsburgh, PA, USA., Srinivasan A; NSABP Foundation, Inc, Pittsburgh, PA, USA.; Lipedema Foundation, Autism Impact Fund, New York, NY, USA., Finnigan M; NSABP Foundation, Inc, Pittsburgh, PA, USA., Wade JL 3rd; Cancer Care Specialists of Illinois/Heartland and NCORP, Decatur Memorial Hospital, Decatur, IL, USA., Buchschacher GL Jr; Kaiser Permanente Southern California, Los Angeles, CA, USA., Al Baghdadi T; Trinity Health IHA Ann Arbor Hospital, Michigan Cancer Research Consortium (NCORP), Ypsilanti, MI, USA., Shipstone A; Ballad Health Cancer Care, Kingsport, TN, USA., Lin D; Thomas Jefferson University Hospital, Philadelphia, PA, USA., Puhalla SL; University of Pittsburgh, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Allegra CJ; NSABP Foundation, Inc, Pittsburgh, PA, USA.; The University of Florida Health Cancer Center, Gainesville, FL, USA., Wolmark N; NSABP Foundation, Inc, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Pogue-Geile KL; NSABP Foundation, Inc, Pittsburgh, PA, USA.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 Aug 09; Vol. 95 (1), pp. 80. Date of Electronic Publication: 2025 Aug 09.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0843
DOI:10.1007/s00280-025-04802-8